انخفاض خسارة ADPT في الربع الأول

What happened: Adaptive Biotechnologies (ADPT) reported Q1 2026 results on May 5. Revenue grew 35% YoY to $70.9 million, driven by strong performance of its clonoSEQ product. Net loss narrowed to $29.8 million, or $0.20 per share, compared to $47.5 million, or $0.33 per share, in Q1 2024.

Market impact: The positive results boosted ADPT's stock, making it one of the best growth stocks under $20 to buy. However, ADENTRA Inc. (ADEN.TO), a competitor in the biotech sector, reported a decline in Q1 earnings, which could weigh on investor sentiment in the sector.

What to watch next: ADPT's Q2 2026 earnings, expected on August 4, will provide insight into whether the strong Q1 performance is sustained. Additionally, investors will be watching for updates on ADPT's pipeline, particularly the phase 3 clinical trial for its multiple myeloma drug, and any further developments from ADENTRA.